French femtech company Fizimed has raised €4 million to accelerate its international expansion and develop innovative women’s health technologies. The funding round was led by the Fonds Patient Autonome managed by Bpifrance, with additional support from UNIQA and UI Investissement.
Founded in 2017 in Strasbourg, Fizimed aims to revolutionize women’s health worldwide by providing innovative and practical solutions tailored to their daily lives. The company is committed to breaking down taboos surrounding women’s health issues, including maternity, menstruation, menopause, and pelvic floor disorders.
“This funding marks a pivotal moment for Fizimed. It will allow us to support even more women worldwide by providing effective and innovative solutions to improve their quality of life. We are proud to contribute to a real transformation in women’s healthcare,” says Emeline Hahn, CEO of Fizimed.
The company’s flagship products include the Emy Trainer, a connected pelvic floor trainer that allows women to strengthen their pelvic muscles at home in a fun and effective way. With thousands of satisfied users, this device addresses urinary incontinence, a condition affecting one in three women. A clinical trial has confirmed the effectiveness of Emy Trainer, further reinforcing its credibility and impact on women’s health.
Jean-Briac Lesné, Investment Director at Bpifrance, noted, “We are delighted to support Fizimed’s international expansion. As a pioneering French femtech company, it has already demonstrated the effectiveness of its solutions and their positive impact on women’s lives.”
With this new funding, Fizimed is set to accelerate its global expansion, particularly in German-speaking countries and the United States—high-potential markets where it already has a subsidiary. The company will also strengthen partnerships with healthcare professionals and enhance awareness campaigns among users. To support its growth, Fizimed will expand its team, develop new products, and continue advancing its expertise worldwide.
The company has already gained traction in Europe, with its pelvic floor trainer now covered by health insurance in Germany. Fizimed benefits from the support of Quest for Health, a leading French health startup accelerator, and EIT (European Institute of Innovation & Technology) via EIT Digital and EIT Health.
“A leading player in European Femtech, Fizimed’s technology is paving the way for a lasting impact on women’s health across Europe,” adds Aurélia Bojmal, Investment Director at UI Investissement.
Fizimed prioritizes high-quality manufacturing, using materials primarily sourced from France, and follows an eco-conscious approach, striving to reduce its carbon footprint and promote responsible production. With a presence in Europe, the United States, and Asia, the company ensures equitable access to healthcare for hundreds of thousands of women across borders.
